Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Lung Neoplasms 1Epilepsy 1

Interventions

Cyclophosphamide 13Temozolomide 10Magnetic Resonance Spectroscopy 10dinutuximab 8X-Rays 8Specimen Handling 8Irinotecan 8Biopsy 8Phantoms, Imaging 7Topotecan 6Nuclear Medicine Department, Hospital 6fludarabine 5Vincristine 53-Iodobenzylguanidine 5fludarabine phosphate 4Granulocyte-Macrophage Colony-Stimulating Factor 4Etoposide 4tipifarnib 3sargramostim 3Radiotherapy 3Melphalan 3Isotretinoin 3Filgrastim 3Doxorubicin 3Carboplatin 3ulixertinib 2tazemetostat 2selpercatinib 2saponin QA-21V1 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × LY3295668 erbumine × 90 days × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡